Study for tremors after pancreas-kidney transplant
Part of Brain & nervous system clinical trials.
This trial tests a treatment approach for people who develop tremors after a combined pancreas and kidney transplant. It aims to improve tremor symptoms while keeping transplant organs functioning steadily.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 70 years old and can understand the study and consent
- You have diabetes type 1 or insulin-dependent type 2 and also have chronic kidney disease
- You received a simultaneous pancreas-kidney (SPK) transplant 3 to 60 months ago
- You have tremors that started after your transplant
- Your pancreas and kidney transplant function is stable (no extra diabetes pills/insulin, and stable lab/enzymes), and you take immediate-release tacrolimus
- If you can get pregnant, you must have a negative pregnancy test before joining
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if empagliflozin, a diabetes medicine that also protects the kidneys, can help people who have received a kidney transplant. It may be an option if you have reduced kidney function or diabetes after transplant.
This trial tests whether transplanting insulin-producing “islet” cells can better control blood sugar in people who have already received a kidney transplant. It’s mainly for adults with type 1 diabetes whose body is no longer making enough insulin, while they are on kidney-transplant medicines.
This study looks at whether Envarsus XR helps prevent “subclinical” (not obviously noticeable) kidney transplant rejection by changing blood immune test results. You may be able to join if you recently received a kidney transplant and can take the study medicine as required.
This study looks at how well a once-daily extended-release tacrolimus (Envarsus) works in real-life for kidney transplant patients. It uses artificial intelligence to help understand treatment patterns and outcomes.
This study looks at people who receive a pancreas transplant, with or without a same-time kidney transplant, and follows them to understand their results. It may help improve how transplant teams choose patients and manage care after surgery.
This study looks at how the anti-rejection drug tacrolimus (specifically Envarsus) affects blood sugar and risk of diabetes in kidney transplant patients. It aims to find out which patients might be more likely to develop glucose problems so doctors can adjust treatment early.
Hear when a new Kidney Pancreas Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.